The clock is ticking on Eli Lilly’s big Alzheimer’s gamble; Pluristem reaches terms on $30M investment from China group
Eli Lilly’s huge solanezumab study is almost done. The pharma company noted this morning that the last patient visit has been recorded in its latest Phase III attempt to prove that the amyloid beta theory for Alzheimer’s is right. Lilly, of course, already had one failed Phase III effort on this drug. But they’re convinced that they can show cognitive benefits for patients with a mild form of the memory-wasting ailment. The data are due out before the end of the year, just weeks away.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
